Applicant: Satoko Shitagaki et al. Attorney's Docket No.: 12732-174001 / US6725

Serial No.: 10/706,291

Filed: November 13, 2003

Page : 9 of 10

REMARKS

Claims 15-27 and 29-32 are pending in this application with claims 15-19 and 30 being independent. Claim 15 has been amended to eliminate the recitation that X and Y each may represent an alkyl group, and claim 30 has been added to affirmatively recite that each of X and Y represents an alkyl group. New dependent claims 31 and 32 correspond to claims 20 and 21. No new matter has been introduced.

Applicant acknowledges with appreciation the Examiner's allowance of claims 16-19, 22-27 and 29, and the Examiner's indication that claim 20 is directed to allowable subject matter.

Claim 15 has been rejected under 35 U.S.C. 102(a) as being anticipated by JP 2003-40873, and claim 21 has been rejected as being unpatentable over JP 2003-40873 in view of Li (U.S. Patent No. 6,723,445). In applicant's prior reply, applicant requested withdrawal of this rejection because JP 2003-40873, which was published on February 13, 2003, does not qualify as prior art with respect to this application, which was filed on November 13, 2003, and claims priority to an application filed in Japan on November 13, 2002. Applicant also noted that a certified translation of the Japanese priority application would be submitted along with an explanation as to why the subject matter of claims 15 and 21 finds support in the priority application.

A certified translation of the Japanese priority application is being submitted with this amendment. Upon review of that translation, applicant determined that the Japanese priority application did not provide support for the recitation that X and Y each may represent an alkyl group. In view of this, applicant has amended claim 15 to eliminate the indication that X and Y each may represent an alkyl group. As amended, claim 15 finds support in claim 19 of the translated Japanese priority application at page 11, lines 14-24. Accordingly, JP 2003-40873 does not qualify as prior art and the rejections should be withdrawn.

New independent claim 30 includes the features of claim 15 except that independent claim 15 affirmatively recites that each of X and Y represents an alkyl group. Claim 30 is believed to be allowable over JP 2003-40873 and Li because neither JP 2003-40873, Li, nor any

Applicant: Satoko Shitagaki et al.

Serial No.: 10/706,291

Filed: November 13, 2003

Page :

: 10 of 10

proper combination of the two describes or suggests a quinoxaline derivative having the formula recited in claim 30 with X and Y each representing an alkyl group.

Applicant submits that all claims are in condition for allowance.

The fee in the amount of \$1,480 in payment of the excess claims fee (\$210), the two-month extension fee (\$460) and the request for continued examination fee (\$810) is being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account authorization. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Attorney's Docket No.: 12732-174001 / US6725

Barbara A. Benoît Lgab S4.777

Barbar A Bennit for

John F. Hayden Reg. No. 37,640

Date: Oct. 15, 2007

Fish & Richardson P.C. 1425 K Street, N.W. 11th Floor

11In Floor

Washington, DC 20005-3500 Telephone: (202) 783-5070 Facsimile: (202) 783-2331

12732 174001 amendment